AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $4.97 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.